White Paper
August 08, 2016

Strategies for effective neutralizing cell-based assays in early immunogenicity risk assessment

Download our white paper to learn about antibody-based immune responses, the role of neutralizing antibody assays, challenges in their design, and the need for a clear immunogenicity strategy to assess and mitigate risk during drug development. Immunogenicity testing and immunoassays can be a crucial component of your product's development and success.

Q2 Solutions services can meet your immunogenicity and immunoassay needs from method development and validation, through sample analysis and customized reporting. Our scientists have extensive experience developing and validating variety of assays that support drug development including ELISA, Electrochemiluminescence (ECL), and cell-based immunoassays.

At Q2 Solutions we can develop and validate custom-designed assays as well as ensure the transfer of existing bioanalytical methods. Contact us to learn more about Q2 Solutions and how we can put our experience and expertise to work for you by providing you with actionable insights for better health.

Paul Rhyne, Ph.D.

Related Services:
Bioanalytical & ADME Laboratory Services

Accelerate and enhance your discovery, preclinical and clinical programs

In Vitro ADME & Metabolite Identification Services List

Services to support your In Vitro ADME development needs

Read More